Neurol. praxi. 2019;20(5):383-387 | DOI: 10.36290/neu.2019.144

Perampanel – what to do with it II?

MUDr. Ondřej Strýček, prof. MUDr. Ivan Rektor CSc.
Centrum pro epilepsie Brno, 1. neurologická klinika LF MU a FN u sv. Anny, Brno
Masarykova univerzita, Středoevropský technologický institut – CEITEC, Centrum neurověd, Brno

Fycompa® (perampanel – PER) is an antiepileptic drug for add-on therapy of focal and generalised epilepsy in patient older than 12 years. It has an unique mechanism of action based on decreasing neuronal hyperexcitability by suppressing glutamatergic transmission. Its interactive potential is low allowing combined therapy with other antiepileptic drugs. It is save and its good tolerability is supported by once-daily dosing. It is effective for treatment focal and tonic-clonic seizures (generalized and focal to bilateral tonic-clonic seizures). It is well-tolerated even in long-term treatment. When rightly use (especially slowly titrated), it can be usable add-on therapy in early phase.

Keywords: epilepsy, treatment, seizure freedom, AMPA receptor, perampanel

Published: November 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Strýček O, Rektor I. Perampanel – what to do with it II? Neurol. praxi. 2019;20(5):383-387. doi: 10.36290/neu.2019.144.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Badawy RA, Vogrin SJ, Lai A, Cook MJ. Capturing the epileptic trait: cortical excitability measures in patients and their unaffected siblings. Brain 2013; 136: 1177-1191. Go to original source... Go to PubMed...
    2. Centellas MF, Alegre VB, Gomara MJG, Pérez ES, Bayarri PG, Balbastre AP, Sanchez CA, Belloch PE, Escrivá AG, Alebesque AV, Valls MB, Tienda AP, Usieto JAO, Dávila-González P, Mascaró RF, Bueno JCR, Fayos GS, Albanell AM, Monteagudo S, Casadevall T, Martínez AB.Effectiveness and tolerability of perampanel in adolescents and adults as a first add-on therapy. An observational multicentre study. 71st Annual Meeting of the American Epilepsy Society, Washington, DC, USA. 2017; 3: 287.
    3. Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, Patten A, Yang H, Williams B, Laurenza A. Final safety, tolerability, andseizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307. Epilepsia 2018; 59: 866-876. Go to original source... Go to PubMed...
    4. Kwan P, Brodie MJ, Laurenza A, FitzGibbon H, Gidal BE. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: impact of mechanism of action and pharmacokinetics on clinical outcomes. Epilepsy research 2015; 117. 117-124. Go to original source... Go to PubMed...
    5. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319. Go to original source... Go to PubMed...
    6. Kwok CS, Johnson EL, Krauss GL. Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment. CNS Drugs 2017; 31: 959-974. Go to original source... Go to PubMed...
    7. Liguori C, Izzi F, Manfredi N, D'Elia A, Mari L, Mercuri NB, Fabio P. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study. Epilepsy Behav 2018; 80: 173-176. Go to original source... Go to PubMed...
    8. Margolis JM, Chu BC, Wang ZJ, Copher R, Cavazos JE. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA neurology 2014; 71(8): 985-993. Go to original source... Go to PubMed...
    9. Maurousset A, Limousin N, Praline J, Biberon J, Corcia P, De Toffol B. Adjunctive perampanel in refractory epilepsy: experience at tertiary epilepsy care center in Tours. Epilepsy Behav 2016; 61: 237-41. Go to original source... Go to PubMed...
    10. Molins A. (2017, 12). Perampanel in Early Add-On Therapy with a Follow-Up of 12 Months. 71st Annual Meeting of the American Epilepsy Society, Washington, DC, USA.
    11. Montoya FJ, Cerveró D, Díaz-Román M, García S. Real-life experience of perampanel in generalized seizures: electroclinical analysis. 71st Annual Meeting of the American Epilepsy Society, Washington, DC, USA. 2017; 3: 170.
    12. Neuray C, Zimmermann G, Villanueva V, Garamendi I, Sander JW, Shankar R, Ben-Menachem E, Brodie MJ, Pensel MC, Wehner T, Di Gennaro G, Maurousset A, Strzelczyk A, Rheims S, Rácz A, Menzler K, Bertol Alegre V, García-Morales I, López-González FJ, Toledo M, Trinka E. Multicentre observational study of perampanel in routine clinical use across Europe: Impact of baseline characteristics on retention over time. Annual Meeting of the American Epilepsy Society, Washington, DC, USA. 2017; 3: 182.
    13. Rektor I, Krauss GL, Inoue Y, Kaneko S, WIlliams B, Patten A, Bibbiani F, Laurenza A, Wechsler RT. Long-term efficacy and safety of adjunctive perampanel in open-label extension (OLEx) studies: post hoc analysis. Epilepsia 2017; 58: S110-S110.
    14. Rektor I, Strýček O. Perampanel - kam s ním? Neurol. praxi 2017; 18(3): 208-211. Go to original source...
    15. Rektor I. Perampanel. A novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures. Expert Opinion on Pharmacotherapy 2013; 14(2): 225-235. Go to original source... Go to PubMed...
    16. Rohracher A, Zimmermann G, Villanueva V, Garamendi I, Sander JW, Wehner T, Shankar R, Ben-Menachem E, Brodie MJ, Pensel MC, Di Gennaro G, Maurousset A, Strzelczyk A, Rheims S, Rácz A, Menzler K, Bertol-Alegre V, García-Morales I, López-González FJ, Toledo M, Carpenter KJ, Trinka E. Perampanel in routine clinical use across Europe: pooled, multicenter, observational data. Epilepsia 2018; 59: 1727-1739. Go to original source... Go to PubMed...
    17. Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia 2014; 55: 13-15. Go to original source... Go to PubMed...
    18. Ryvlin P, Nashef L, Lhatoo SD, Bateman L M, Bird J, Bleasel A, Lerche H. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. The Lancet Neurology 2012; 12(10): 966-977. Go to original source... Go to PubMed...
    19. Snoeijen-Schouwenaars FM, van Ool JS, Tan IY, Schelhaas HJ, Majoie MHJM. Evaluation of perampanel in patients with intellectual disability and epilepsy. Epilepsy Behav 2017; 66: 64-67. Go to original source... Go to PubMed...
    20. Sperling M, Wiliams B, Laurenza A, Patten A, Yang H. Efficacy of perampanel by baseline seizure frequency in patients with partial seizures. 12th European Congress on Epileptology, Prague, Czech Republic, 2016: 594.
    21. Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, Squillacote D, Yang H, Zhu J, Laurenza A. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia 2013; 54(8): 1481-1489. Go to original source... Go to PubMed...
    22. Stephen LJ, Wishart A, Brodie MJ. Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. Epilepsy Behav 2017; 71(Pt A): 73-78. Go to original source... Go to PubMed...
    23. Tellez-Zenteno J, Nguyen R. Injuries in epilepsy: a review of its prevalence, risk factors, type of injuries and prevention. Neurology international. 2009; 1(1): 20. Go to original source... Go to PubMed...
    24. Templeton D. Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Epilepsia 2009; 50(Suppl. 11): abstract 1.199. Go to PubMed...
    25. Tyrlikova I, Brazdil M, Rektor I, Tyrlik M. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures. Expert Rev Neurother 2019; 19(1): 5-16. Go to original source... Go to PubMed...
    26. Villanueva V, Garce's M, López-González FJ, Rodriguez-Osorio X, Toledo M, Salas-Puig J, González-Cuevas M, Campos D, Serratosa JM, González-Giráldez B, Mauri JA, Camacho JL, Suller A, Carre?o M, Gómez JB, Montoya J, Rodríguez-Uranga J, Saiz-Diaz R, González-de la Aleja J, Castillo A, López-Trigo J, Poza JJ, Flores J, Querol R, Ojeda J, Giner P, Molins A, Esteve P, Baiges JJ. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study. Epilepsy Res 2016; 126: 201-10. Go to original source... Go to PubMed...
    27. Villanueva V, Montoya J, Castillo A, Mauri-Llerda JÁ, Giner P, López-González FJ, Piera A, Villanueva-Hernández P, Bertol V, Garcia-Escrivá A, Garcia-Pe?as JJ, Garamendi I, Esteve-Belloch P, Baiges-Octavio JJ, Miró J, Falip M, Garcés M, Gómez A, Gil-López FJ, Carre?o M, Rodriguez-Uranga JJ, Campos D, Bonet M, Querol R, Molins A, Tortosa D, Salas-Puig J. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study. Epilepsia 2018; 59: 1740-1752. Go to original source... Go to PubMed...
    28. Zhu LN, Chen D, Xu D, Tan G, Wang HJ, Liu L. Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: An indirect comparison. Seizure 2017; 51: 121-132. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.